J. Gibson

发表

Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma

D. Joshua, Ross D. Brown, A. Spencer, 2009, Leukemia & lymphoma.

Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia

M. Fulham, J. Szer, A. Zannettino, 2021, Internal medicine journal.

Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma

Peter Shaw, S. Ramanathan, C. Tiley, 2022, European Journal of Clinical Pharmacology.

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade

N. Nassif, C. Weatherburn, D. Joshua, 2016, Leukemia.

Frequency of infection in plateau-phase multiple myeloma

L. Snowdon, D. Joshua, J. Gibson, 1994, The Lancet.

Longitudinal analysis of circulating myeloma cells detected by allele specific mRNA in situ hybridization

A. Morley, D. Joshua, Ross D. Brown, 1998, American journal of hematology.

Interleukin 4 and 6 Receptor Expression on B Cell Lines and the Lymphocytes of Patients with B Cell Malignancies

D. Joshua, Ross D. Brown, B. Gorenc, 1992 .

from the Ig heavy chain gene phase to progression does not involve a new B-cell clone: evidence Advancement of multiple myeloma from diagnosis through plateau

A. Morley, Ross D. Brown, M. Brisco, 2011 .

Hemodialysis: an appropriate therapy in myeloma-induced renal failure.

D. Tiller, D. Joshua, L. Snowdon, 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

CD86 (cid:1) or HLA-G (cid:1) can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis

N. Nassif, D. Joshua, Ross D. Brown, 2012 .

Interferon-alpha in the treatment of multiple myeloma.

A. Vangsted, D. Joshua, J. Gibson, 2011, Current drug targets.

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

N. Nassif, D. Joshua, Ross D. Brown, 2013, Blood Cancer Journal.

Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+)CD57(+)CD28(-) compartment.

A. Basten, B. Fazekas de St. Groth, J. Ho, 2001, Blood.

Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group

A. Zannettino, J. Szer, A. Roberts, 2015, Internal medicine journal.

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group

A. Zannettino, J. Szer, A. Roberts, 2015, Internal medicine journal.

T cells in myeloma

D. Joshua, Ross D. Brown, R. Brown, 2003, Hematological oncology.

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

D. Joshua, Ross D. Brown, D. Hart, 2001, Blood.